+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Asia Gout Disease Treatment Market - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027

  • ID: 5327593
  • Report
  • September 2020
  • Region: Asia Pacific
  • Coherent Market Insights Pvt Ltd.

FEATURED COMPANIES

  • AstraZeneca Plc
  • Horizon Therapeutics plc
  • LG Chem
  • Teijin Pharma Limited
  • Zyla Life Sciences
  • MORE
Gout is a chronic disease characterized by the pain and inflammation in the joints. It is also known as gout arthritis, in which high level of uric acid in blood leads to formation of needle-like crystals in the joints resulting in inflammation and pain. This condition can be treated or prevented with the use of drugs such as nonsteroidal anti-inflammatory drugs, corticosteroids, colchicine, and urate-lowering agents. Moreover, monoclonal antibody is also used to treat gout in certain cases in which, nonsteroidal anti-inflammatory drugs, corticosteroids, colchicine, and urate lowering agents are unresponsive to the patient.

Market Dynamics

Increasing prevalence of gout disease is expected to increase demand of anti-gout drugs, which is expected to drive growth of the Asia gout disease treatment market growth over the forecast period. For instance, according to the National Center for Biotechnology Information (NCBI) (Rheumatology journal), the prevalence of gout in 2015 increased in South Korea compared to 2007 (earlier reported prevalence). In 2007, the prevalence of gout disease in South Korea was 3.49 (3.48-3.51) per 1,000 persons and in 2015, the prevalence of gout disease in South Korea was 7.58 (7.55-7.60) per 1,000 persons. Moreover, according to the data from the Australian Bureau of Statistics 2017–2018 (a National Health Survey), an estimated 187,000 people of Australia (0.8% of the Australia population) were diagnosed with gout disease in 2017.

Moreover, increasing product approvals by regulatory authorities is expected to drive growth of the Asia gout disease treatment market. For instance, in December 2018, SunGen Pharma, a privately held company, received the U.S. FDA approval for Prednisone (generic version of Deltasone), a drug with various strengths 10 mg, 20 mg, and 50 mg tablets, to treat various conditions such as arthritis, gout, blood disorders, immune system disorders, and others.

Key features of the study:
  • This report provides in-depth analysis of the Asia gout disease treatment market, market size and compound annual growth rate (CAGR (XX %)) for the forecast period: 2020-2027, considering 2019 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the Asia gout disease treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include AstraZeneca Plc, Takeda Pharmaceutical Company Limited, Teijin Pharma Limited, Hikma Pharmaceuticals Plc., Zyla Life Sciences, Horizon Therapeutics plc, JW Pharmaceutical CORPORATION, and LG Chem
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The Asia gout disease treatment market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for gout disease treatment market, research and consulting firms, new entrants, and financial analysts
Detailed Segmentation:

Asia Gout Disease Treatment Market, By Drug Class:
  • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
  • Corticosteroids
  • Colchicine
  • Urate-lowering Agents
Asia Gout Disease Treatment Market, By Route of Administration:
  • Oral
  • Injectable
Asia Gout Disease Treatment Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
Asia Gout Disease Treatment Market, By Country:
  • China
  • India
  • Japan
  • South Korea
  • Thailand
  • Indonesia
  • Singapore
  • Vietnam
  • Rest of Asian Countries
  • Company Profiles
  • AstraZeneca Plc
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • Takeda Pharmaceutical Company Limited
  • Teijin Pharma Limited
  • Hikma Pharmaceuticals Plc.
  • CymaBay Therapeutics, Inc.
  • Zyla Life Sciences
  • Horizon Therapeutics plc
  • JW Pharmaceutical CORPORATION
  • LG Chem
“*” marked represents similar segmentation in other categories in the respective section.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AstraZeneca Plc
  • Horizon Therapeutics plc
  • LG Chem
  • Teijin Pharma Limited
  • Zyla Life Sciences
  • MORE
1. Research Objectives and Assumptions
  • Research Objectives
  • Assumptions
  • Abbreviations
2. Market Overview
  • Report Description
  • Market Definition and Scope
  • Executive Summary
  • Market Snippet, By Drug Class
  • Market Snippet, By Route of Administration
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Country
  • Opportunity Map
3. Market Dynamics, Regulations, and Trends Analysis
  • Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
  • Impact Analysis
  • Pipeline Analysis
  • Regulatory Scenario
  • Reimbursement Scenario
  • Key Developments
  • PEST Analysis
  • Epidemiology
4. Covid - 19 Impact Analysis
  • Pre-COVID 19 Market Situation
  • Post Covid - 19 Market Scenario
  • Overall Impact on the Healthcare Industry
5. Asia Gout Disease Treatment Market, By Drug Class, 2016 - 2027, (US$ Million)
  • Introduction
  • Market Share Analysis, 2020 and 2027 (%)
  • Y-o-Y Growth Analysis, 2017 - 2027
  • Segment Trends
  • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Corticosteroids
Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Colchicine
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Urate-lowering Agents
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
6. Asia Gout Disease Treatment Market, By Route of Administration, 2016 - 2027, (US$ Million)
  • Introduction
  • Market Share Analysis, 2020 and 2027 (%)
  • Y-o-Y Growth Analysis, 2017 - 2027
  • Segment Trends
  • Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Injectable
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
7. Asia Gout Disease Treatment Market, By Distribution Channel, 2016 - 2027, (US$ Million)
  • Introduction
  • Market Share Analysis, 2020 and 2027 (%)
  • Y-o-Y Growth Analysis, 2017 - 2027
  • Segment Trends
  • Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
8. Asia Gout Disease Treatment , By Country, 2016 - 2027, (US$ Million)
  • Introduction
  • Market Share Analysis, By Region, 2020 and 2027 (%)
  • Y-o-Y Growth Analysis, By Region, 2017 - 2027
  • Regional Trends
  • China
  • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Million)
  • Market Size and Forecast, By Route of Administration, 2016 - 2027, (US$ Million)
  • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
  • India
  • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Million)
  • Market Size and Forecast, By Route of Administration, 2016 - 2027, (US$ Million)
  • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
  • Japan
  • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Million)
  • Market Size and Forecast, By Route of Administration, 2016 - 2027, (US$ Million)
  • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
  • South Korea
  • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Million)
  • Market Size and Forecast, By Route of Administration, 2016 - 2027, (US$ Million)
  • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
  • Thailand
  • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Million)
  • Market Size and Forecast, By Route of Administration, 2016 - 2027, (US$ Million)
  • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
  • Indonesia
  • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Million)
  • Market Size and Forecast, By Route of Administration, 2016 - 2027, (US$ Million)
  • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
  • Singapore
  • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Million)
  • Market Size and Forecast, By Route of Administration, 2016 - 2027, (US$ Million)
  • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
  • Vietnam
  • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Million)
  • Market Size and Forecast, By Route of Administration, 2016 - 2027, (US$ Million)
  • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
  • Rest of Asian Countries
  • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Million)
  • Market Size and Forecast, By Route of Administration, 2016 - 2027, (US$ Million)
  • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
9. Competitive Landscape
  • Company Profiles
  • AstraZeneca Plc
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • Takeda Pharmaceutical Company Limited
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • Teijin Pharma Limited
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • Hikma Pharmaceuticals Plc.
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • CymaBay Therapeutics, Inc.
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • Zyla Life Sciences
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • JW Pharmaceutical CORPORATION
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • LG Chem
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
10. Section
  • References
  • Research Methodology
  • About us and Sales Contact
Note: Product cover images may vary from those shown
  • AstraZeneca Plc
  • Takeda Pharmaceutical Company Limited
  • Teijin Pharma Limited
  • Hikma Pharmaceuticals Plc.
  • CymaBay Therapeutics, Inc.
  • Zyla Life Sciences
  • Horizon Therapeutics plc
  • JW Pharmaceutical CORPORATION
  • LG Chem
Note: Product cover images may vary from those shown
Adroll
adroll